首页 | 本学科首页   官方微博 | 高级检索  
   检索      


Development of a Serum-free Suspension Process for the Production of a Conditionally Replicating Adenovirus using A549 Cells
Authors:Robert Longley Jr  Laurie Radzniak  Marc Santoro  Yung-Shyeng Tsao  Russell G G Condon  Peggy Lio  Marcio Voloch  Zhong Liu
Institution:(1) Biotechnology Development, Schering-Plough Research Institute, U2-1300, 1011 Morris Avenue, Union, NJ 07083, USA
Abstract:Conditionally replicating adenoviruses (CRAVs) are a group of recombinant human adenoviruses genetically engineered to replicate in selected tissues, such as tumors. These viruses could potentially offer significant medicinal benefits, since the restrictive replication of these viral vectors leads to the lysis of target cells without harm to the surrounding tissues. The in vitro propagation and amplification of the CRAV vectors often requires special host cells with deregulated growth control pathways. In order to develop an efficient cell culture process for the scaleable production of a CRAV vector, A549 cells, a human lung carcinoma cell line normally cultured in adherent culture, were adapted to suspension culture. CRAV production was demonstrated with the suspension-adapted A549 cells and a baseline production process was developed in shake flasks. The ability to scale-up virus production was confirmed in stirred tank bioreactors. Molecular characterization of the suspension-adapted A549 cells indicates no significant changes in cellular mechanisms related to adenovirus infection.
Keywords:Adenovirus  Recombinant adenovirus  Gene therapy  A549 cells  Serum-free  Suspension  Conditionally replicating adenoviruses (CRAVs)
本文献已被 SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号